When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...
Hospitals affiliated with Mount Sinai, the University of Michigan and the University of Kansas allege that CVS artificially ...
With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...
On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...
This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...
Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 ...
On July 31, 2025, the Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA) issued a 340B Drug Pricing Program notice (the “Notice”) announcing the launch of a ...
The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...
When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...
If HHS’ 340B rebate model pilot proceeds as planned, more than 2,700 U.S. hospitals will collectively be saddled with approximately $400 million in operational costs and 11.2 million labor burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results